Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

Show other versions (1)

<h4>Aims</h4> A Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with non-valvular atrial fibri...

Full description

Bibliographic Details
Main Authors:	Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020681/?tool=EBI

Similar Items

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
by: Carlos Escobar Cervantes, et al.
Published: (2022-01-01)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
by: Kevin Bowrin, et al.
Published: (2020-01-01)

Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry
by: Eric Durand, et al.
Published: (2024-01-01)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France.
by: Kevin Bowrin, et al.
Published: (2020-01-01)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
by: Craig I. Coleman, et al.
Published: (2019-01-01)

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
by: J. M. van den Heuvel, et al.
Published: (2018-04-01)

Systematic review of pharmacoeconomic models for schizophrenia
by: Junwen Zhou, et al.
Published: (2018-01-01)

Economic impact of a triptan Rx-to-OTC switch in six EU countries.
by: Aurelie Millier, et al.
Published: (2013-01-01)

Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
by: Pierre Levy, et al.
Published: (2019-01-01)

Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type
by: Ceren Eyileten, et al.
Published: (2020-04-01)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
by: Junwen Zhou, et al.
Published: (2019-01-01)

Some Thoughts About Warfarin and NOACS
by: C. Richard Conti
Published: (2017-01-01)

The Viktorоvka-I settlement of the Late Archaic time
by: Denis Bondarenko
Published: (2018-11-01)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population
by: Mondher Toumi, et al.
Published: (2020-07-01)

Low-Dose NOACs Versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Asian Patients with NVAF: A Meta-Analysis
by: Zei Li, et al.
Published: (2022-06-01)

Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation.
by: Alberto Tosetto, et al.
Published: (2015-01-01)

Determinants of orphan drugs prices in France: a regression analysis
by: Daria Korchagina, et al.
Published: (2017-04-01)

TAVR, NOACs, NAFLD, and a Happy New Year
by: Çetin Erol
Published: (2019-12-01)

Warfarin involvement, in comparison to NOACs, in the development of systemic atherosclerosis
by: Romeo Gabriel Mihaila
Published: (2022-05-01)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
by: Mondher Toumi, et al.
Published: (2017-01-01)

Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms
by: Angela Saviano, et al.
Published: (2022-11-01)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review
by: Chiraz Azaiez, et al.
Published: (2018-01-01)

Draft genome of Meyerozyma guilliermondii strain vka1: a yeast strain with composting potential
by: Ravisankar Valsalan, et al.
Published: (2020-09-01)

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
by: Blann A
Published: (2015-08-01)

Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study
by: Pierre Ménager, et al.
Published: (2020-12-01)

Case report: Application of non-VKA oral anticoagulants in patient of idiopathic hypereosinophilic syndrome with intracardiac thrombus
by: Man Zou, et al.
Published: (2022-09-01)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
by: Sarlon Emmanuelle, et al.
Published: (2012-08-01)

Novel Oral Anti Coagulants (NOACs) as Anti Thrombotic on Atrial Fibrillation Patients
by: Abed Nego Okthara Sebayang
Published: (2020-02-01)

Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY
by: Christina Köhler, et al.
Published: (2023-07-01)

Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis
by: Line Melgaard, et al.
Published: (2021-12-01)

Non-vitamin K oral anticoagulants (NOACs) in patients with stroke and atrial fibrillation
by: Jovanović Dejana R.
Published: (2020-01-01)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement.
by: Victor Chien-Chia Wu, et al.
Published: (2020-01-01)

Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease.
by: Judith Kooiman, et al.
Published: (2014-01-01)

Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
by: Anetta Undas, et al.
Published: (2019-12-01)

Correction: New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
by: Karen Sheares, et al.
Published: (2020-06-01)

Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY
by: Jan Beyer-Westendorf, et al.
Published: (2021-12-01)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
by: Caroline Sindet-Pedersen, et al.
Published: (2017-06-01)

Atualizações em Coagulação: Os Anticoagulantes Orais Não Antagonistas da Vitamina K (NOACs)
by: Isabel Vitória Figueiredo, et al.
Published: (2019-02-01)

Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis
by: Lu Wang, et al.
Published: (2023-08-01)

Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study.
by: Agnes Rouaud, et al.
Published: (2015-01-01)